News | Structural Heart Occluders | February 01, 2017

Amplatzer PFO Occluder Now Available at Baylor Heart and Vascular Services at Fort Worth

First two Texas patients received device designed to reduce the risk of recurrent cryptogenic strokes in November

Amplatzer PFO Occluder, St. Jude Medical, Baylor Heart and Vascular Services, Fort Worth, Texas, first patients

February 1, 2017 — Baylor Heart and Vascular Services at Fort Worth in November became the first program in Texas to implant the Amplatzer PFO Occluder. The device is designed to help reduce the risk of recurrent cryptogenic strokes in patients diagnosed with a patent foramen ovale (PFO) – a small opening between the upper chambers of the heart.

The Baylor Hamilton Heart and Vascular Hospital team implanted the new device into two patients with PFO at Baylor Scott & White All Saints Medical Center – Fort Worth.

The Amplatzer PFO Occluder is the first and only U.S. Food and Drug Administration (FDA)-approved device designed to close the PFO and lower the risk of stroke caused by dangerous clots passing between the heart chambers and up to the brain.

Normally in a developing fetus, the foramen ovale allows oxygenated blood from the placenta to bypass the lungs. This small, flap-like opening typically closes shortly after birth. When this flap remains open, or "patent," it is referred to as a PFO. A PFO can potentially allow dangerous clots to pass from the right side of the heart to the left, travel up to the brain and cause a stroke. The Amplatzer PFO Occluder is designed to seal the unwanted hole and reduce this risk. It is estimated that 25 percent of adults have a PFO, which is often not detected until they have a stroke from an unknown cause, also known as a cryptogenic stroke. Newly released, long-term data from RESPECT, a landmark clinical trial, showed that patients who received the Amplatzer Occluder had a reduced risk of recurrent stroke by 45 percent over guideline-directed medical therapy alone.

Placement of the device is minimally invasive and performed while the patient is sedated but still conscious. Data from the RESPECT trial also show that PFO closure with the device has a low risk of device or procedure-related complications.

For more information: www.sjm.com


Related Content

News | Cath Lab

May 16, 2023 — Royal Philips, a global leader in health technology, announced late-breaking data from the DCR4Contrast ...

Home May 16, 2023
Home
News | Cath Lab

March 14, 2023 — Royal Philips, a global leader in health technology, and the Gibraltar Health Authority, announced they ...

Home March 14, 2023
Home
News | Cath Lab

March 1, 2023 — SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for ...

Home March 01, 2023
Home
News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
Subscribe Now